Exhibit 99.1

    Diagnostic Products Corporation Announces Annual Meeting Date

    LOS ANGELES--(BUSINESS WIRE)--June 17, 2005--Diagnostic Products
Corporation (NYSE:DP) today announced that it will hold its annual
meeting of shareholders on September 8, 2005. The record date to
determine the shareholders entitled to receive notice of the meeting
and to vote at the meeting will be July 15, 2005. Shareholders
interested in submitting a proposal for inclusion in the Company's
proxy statement for the annual meeting must submit such proposal to
the Company no later than July 8, 2005, and must otherwise comply with
the requirements of SEC Rule 14a-8. In addition, the proxy solicited
by the Board of Directors for the annual meeting will confer
discretionary authority to vote on any shareholder proposal presented
at the meeting other than pursuant to Rule 14a-8, unless the Company
receives notice of such proposal on or before July 8, 2005.
Shareholder proposals should be addressed to the Secretary of the
Company at its executive offices located at 5210 Pacific Concourse
Drive, Los Angeles, California 90045.

    Diagnostic Products Corporation, founded in 1971, is the global
leader dedicated exclusively to immunodiagnostics. DPC's product menu
includes over 75 immunoassays and more than 360 specific allergens and
allergy panels. In addition, DPC addresses the chemistry and
laboratory automation testing needs of its customers through
partnerships with manufacturers of chemistry systems and reagents. The
combined chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested. DPC
also designs and manufactures automated laboratory instrumentation,
which provides fast, accurate results while reducing labor and reagent
costs. DPC sells its products to hospitals, clinics and laboratories
in more than 100 countries. Additional Company information can be
found on DPC's Web site at www.dpcweb.com.

    Except for the historical information contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially.
These factors include the effects of governmental or other actions
relating to the FDA's decision that its Application Integrity Policy
should be applied to the Company or relating to the Company's Chinese
affiliate; the rate of customer demand for the Company's products; the
Company's ability to successfully market new and existing products;
its dependence on certain suppliers; domestic and foreign government
regulation; its ability to keep abreast of technological innovations
and to translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC reports
and filings.

    CONTACT: Diagnostic Products Corporation
             James L. Brill, 310-645-8200